What is BEONE MEDICINES LTD's earnings per share (EPS)?

BEONE MEDICINES LTD (BEIGF) reported diluted earnings per share of $0.19 for fiscal year 2025. This represents a 140.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BEONE MEDICINES LTD (BEIGF) Financials

BEIGF

Trailing 12 months to June 30, 2026

Revenue $6.1B +34.3% YoY

Net Income $655.7M +469.1% YoY

EPS (Diluted) $0.43 +407.1% YoY

Free Cash Flow $1.3B +443.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BEIGF SEC filings page.

BEONE MEDICINES LTD (BEIGF) reported $6.1B in revenue over the twelve months to Jun 30, 2026, up 34.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BEIGF FY2025 2026-08-29

Rapid revenue scale converted heavy research spending into operating profit and cash generation, while leverage increased from a low base.

FY2025 marked an earnings-quality inflection: operating margin moved from -14.9% in FY2024 to 8.4%, while operating cash flow swung from -$141M to $1.13B. Cash generation therefore outpaced reported net income of $287M, indicating that the new profitability was accompanied by substantial non-income-statement cash release rather than merely an accounting improvement.

Gross margin widened from 84.4% to 87.5% as revenue reached $5.34B, but the larger change occurred below gross profit: gross-profit growth exceeded the combined expansion of SG&A and R&D, allowing operating leverage to turn a $568M loss into $447M of operating income.

The balance sheet supported the expansion without extreme leverage: the current ratio improved to 3.4x, while debt-to-equity rose to 0.2x from 0.1x. Higher liabilities and long-term debt alongside increased equity suggest the growth was funded through a broader capital base, not cash generation alone.

Financial Health Signals

Financial health score not available

BEONE MEDICINES LTD does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

5.12

BEONE MEDICINES LTD scores 5.12, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($32.3B) relative to total liabilities ($3.8B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

BEONE MEDICINES LTD passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

3.93x

For every $1 of reported earnings, BEONE MEDICINES LTD generates $3.93 in operating cash flow ($1.1B OCF vs $286.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

8.95x

BEONE MEDICINES LTD earns $8.95 in operating income for every $1 of interest expense ($447.1M vs $50.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.7B

YoY+29.6%

QoQ+12.7%

5Y CAGR+62.6%

BEONE MEDICINES LTD generated $1.7B in revenue in Q2 2026. This represents an increase of 29.6% from the same quarter a year earlier. Against the prior quarter it is up 12.7%.

EBITDA

$365.6M

YoY+196.0%

QoQ+25.6%

BEONE MEDICINES LTD's EBITDA was $365.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 196.0% from the same quarter a year earlier. Against the prior quarter it is up 25.6%.

Net Income

$237.0M

YoY+151.3%

QoQ+4.2%

BEONE MEDICINES LTD reported $237.0M in net income in Q2 2026. This represents an increase of 151.3% from the same quarter a year earlier. Against the prior quarter it is up 4.2%.

EPS (Diluted)

$0.16

YoY+166.7%

QoQ+6.7%

BEONE MEDICINES LTD earned $0.16 per diluted share (EPS) in Q2 2026. This represents an increase of 166.7% from the same quarter a year earlier. Against the prior quarter it is up 6.7%.

Cash & Balance Sheet

Free Cash Flow

$435.3M

YoY+98.1%

QoQ+171.2%

BEONE MEDICINES LTD generated $435.3M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 98.1% from the same quarter a year earlier. Against the prior quarter it is up 171.2%.

Cash & Debt

$5.1B

YoY+85.0%

QoQ+6.4%

5Y CAGR+23.5%

10Y CAGR-21.6%

BEONE MEDICINES LTD held $5.1B in cash against $882.2M in long-term debt as of Q2 2026.

Shares Outstanding

1.48B

YoY+3.3%

QoQ+2.3%

5Y CAGR+4.1%

10Y CAGR+13.2%

BEONE MEDICINES LTD had 1.48B shares outstanding in Q2 2026. This represents an increase of 3.3% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

89.8%

YoY+2.3pp

QoQ+0.8pp

5Y change+13.9pp

BEONE MEDICINES LTD's gross margin was 89.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.

Operating Margin

19.1%

YoY+12.4pp

QoQ+2.5pp

BEONE MEDICINES LTD's operating margin was 19.1% in Q2 2026, reflecting core business profitability. This is up 12.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.5 percentage points.

Net Margin

13.9%

YoY+6.7pp

QoQ-1.1pp

BEONE MEDICINES LTD's net profit margin was 13.9% in Q2 2026, showing the share of revenue converted to profit. This is up 6.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.

Return on Equity

4.6%

YoY+2.1pp

QoQ-0.2pp

5Y change+17.9pp

10Y change+15.5pp

BEONE MEDICINES LTD's ROE was 4.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Capital Allocation

R&D Spending

$612.3M

YoY+16.6%

QoQ+13.1%

5Y CAGR+11.4%

BEONE MEDICINES LTD invested $612.3M in research and development in Q2 2026. This represents an increase of 16.6% from the same quarter a year earlier. Against the prior quarter it is up 13.1%.

Capital Expenditures

$27.5M

YoY-37.3%

QoQ-32.6%

5Y CAGR-6.5%

10Y CAGR-41.1%

BEONE MEDICINES LTD invested $27.5M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 37.3% from the same quarter a year earlier. Against the prior quarter it is down 32.6%.

Share Buybacks

Not reported for Q2 2026.

BEIGF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BEIGF quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	$6.1B	$5.3B+40.2%	$3.8B+55.0%	$2.5B+73.7%	$1.4B+20.4%	$1.2B+280.8%	$308.9M-27.9%	$428.2M+116.0%	$198.2M-16.8%	$238.4M+22179.2%	$1.1M-87.9%	$8.8M-32.4%	$13.0M
Cost of Revenue	N/A	N/A	N/A	N/A	$286.5M+73.7%	$164.9M+133.4%	$70.7M-0.7%	$71.2M+148.0%	$28.7M+477.1%	$5.0M	$0	N/A	N/A
Gross Profit	$5.4B	$4.7B+45.3%	$3.2B+54.7%	$2.1B+84.1%	$1.1B+11.7%	$1.0B+324.6%	$238.2M-33.3%	$357.0M+110.6%	$169.5M-27.4%	$233.4M+21714.3%	$1.1M	N/A	N/A
R&D Expenses	$2.3B	$2.1B+9.9%	$2.0B+9.8%	$1.8B+8.4%	$1.6B+12.4%	$1.5B+12.7%	$1.3B+39.6%	$927.3M+36.6%	$679.0M+152.4%	$269.0M+174.4%	$98.0M+68.3%	$58.3M+166.4%	$21.9M
SG&A Expenses	$2.2B	$2.1B+13.7%	$1.8B+21.4%	$1.5B+17.9%	$1.3B+29.1%	$990.1M+65.0%	$600.2M+54.6%	$388.2M+98.7%	$195.4M+212.1%	$62.6M+211.5%	$20.1M+174.9%	$7.3M+5.5%	$6.9M
Operating Income	$923.1M	$447.1M+178.7%	-$568.2M+53.0%	-$1.2B+32.5%	-$1.8B-24.4%	-$1.4B+13.2%	-$1.7B-72.7%	-$959.9M-36.0%	-$705.8M-616.8%	-$98.5M+15.9%	-$117.1M-106.3%	-$56.7M-260.1%	-$15.8M
EBITDA	N/A	$588.8M+248.5%	-$396.4M+64.6%	-$1.1B+35.0%	-$1.7B-23.8%	-$1.4B+14.4%	-$1.6B-72.7%	-$941.3M-35.4%	-$695.4M-642.1%	-$93.7M+18.6%	-$115.2M-108.6%	-$55.2M-288.7%	-$14.2M
Interest Expense	$97.6M	$50.0M+6.5%	$46.9M+125.5%	$20.8M-4.1%	$21.7M-25.8%	$29.3M+59.8%	$18.3M+20.8%	$15.2M+15.3%	$13.1M+420.0%	-$4.1M-1172.6%	$383K-31.5%	$559K+115.9%	-$3.5M
Income Tax	$212.4M	$129.9M+16.2%	$111.8M+100.1%	$55.9M+30.6%	$42.8M+122.5%	$19.2M+84.9%	$10.4M+48.7%	$7.0M+144.3%	-$15.8M-806.8%	$2.2M+4038.9%	$54K	$0	$0
Net Income	$655.7M	$286.9M+144.5%	-$644.8M+26.9%	-$881.7M+56.0%	-$2.0B-37.5%	-$1.5B+10.3%	-$1.6B-71.3%	-$948.6M-40.8%	-$673.8M-623.7%	-$93.1M+21.9%	-$119.2M-108.8%	-$57.1M-212.4%	-$18.3M
EPS (Basic)	N/A	$0.20+142.6%	-$0.47+27.7%	-$0.65+56.4%	-$1.49-23.1%	-$1.21+19.3%	-$1.50-23.0%	-$1.22	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.43	$0.19+140.4%	-$0.47+27.7%	-$0.65+56.4%	-$1.49-23.1%	-$1.21+19.3%	-$1.50-23.0%	-$1.22	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	1.47B+7.8%	1.37B+0.9%	1.36B+1.2%	1.34B+11.2%	1.21B+11.2%	1.09B+39.0%	781M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.7B+29.6%	$1.5B+35.5%	$1.5B+32.8%	$1.4B+41.0%	$1.3B+41.6%	$1.1B+48.6%	$1.1B+77.8%	$1.0B+28.2%
Gross Profit	$1.5B+33.0%	$1.3B+41.4%	$1.4B+40.2%	$1.2B+46.3%	$1.2B+45.5%	$952.3M+51.9%	$967.3M+83.0%	$831.1M+21.3%
R&D Expenses	$612.3M+16.6%	$541.2M+12.3%	$615.4M+13.5%	$523.7M+5.5%	$524.9M+15.5%	$481.9M+4.6%	$542.0M+9.7%	$496.2M+9.5%
SG&A Expenses	$593.2M+10.3%	$555.1M+20.9%	$555.3M+10.0%	$529.0M+16.2%	$537.9M+21.2%	$459.3M+7.5%	$504.7M+20.5%	$455.2M+24.5%
Operating Income	$325.0M+269.9%	$249.9M+2151.0%	$185.0M+333.0%	$163.1M+235.6%	$87.9M+182.0%	$11.1M+104.2%	-$79.4M+79.3%	-$120.3M+10.2%
EBITDA	$365.6M+196.0%	$291.0M+562.9%	$221.0M+857.5%	$200.4M+509.2%	$123.5M+250.2%	$43.9M+118.6%	-$29.2M+91.9%	-$49.0M+56.5%
Interest Expense	$39.7M+229.8%	$32.9M+153.7%	$12.3M+77.0%	$12.7M-11.6%	$12.0M-9.0%	$13.0M+4.5%	$6.9M+47.6%	$14.3M+115.9%
Income Tax	$75.5M+1343.0%	$31.9M+62.3%	$82.7M+24.4%	$22.3M-3.1%	$5.2M-63.9%	$19.6M+154.1%	$66.5M+296.5%	$23.0M+65.5%
Net Income	$237.0M+151.3%	$227.4M+17802.1%	$66.5M+143.8%	$124.8M+202.9%	$94.3M+178.3%	$1.3M+100.5%	-$151.9M+58.7%	-$121.3M-156.3%
EPS (Basic)	$0.16+128.6%	$0.16	$0.04+136.4%	$0.09+200.0%	$0.07+177.8%	$0.00+100.0%	-$0.11+59.3%	-$0.09-156.3%
EPS (Diluted)	$0.16+166.7%	$0.15	$0.04+136.4%	$0.08+188.9%	$0.06+166.7%	$0.00+100.0%	-$0.11+59.3%	-$0.09-160.0%
Diluted Shares (Avg)	1.51B+2.9%	1.51B+4.1%	N/A	1.49B+8.1%	1.46B+7.5%	1.45B+6.6%	N/A	1.38B-1.0%

Not reported in any period shown, so not listed: Cost of Revenue.

BEIGF Balance Sheet

BEIGF quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$8.2B+38.3%	$5.9B+2.0%	$5.8B-9.0%	$6.4B-25.3%	$8.5B+52.4%	$5.6B+247.4%	$1.6B-28.3%	$2.2B+115.0%	$1.0B+157.9%	$405.8M+247.5%	$116.8M	N/A
Current Assets	$6.2B+56.2%	$4.0B-5.0%	$4.2B-19.3%	$5.2B-31.6%	$7.6B+53.5%	$5.0B+323.0%	$1.2B-39.7%	$1.9B+112.8%	$913.5M+144.0%	$374.4M+252.3%	$106.3M	N/A
Cash & Equivalents	$4.5B+73.1%	$2.6B-17.2%	$3.2B-18.0%	$3.9B-11.6%	$4.4B+216.6%	$1.4B+123.6%	$618.0M-13.3%	$712.9M+197.6%	$239.6M+173.8%	$87.5M+389.8%	$17.9M+28.6%	$13.9M
Short-Term Investments	$0	$0-100.0%	$2.6M-99.6%	$665.3M-70.3%	$2.2B-31.4%	$3.3B+796.2%	$364.7M-65.9%	$1.1B+78.7%	$597.9M+113.0%	$280.7M+239.7%	$82.6M	$0
Inventory	$608.2M+22.9%	$495.0M+19.0%	$416.1M+47.4%	$282.3M+16.4%	$242.6M+171.7%	$89.3M+212.7%	$28.6M+75.8%	$16.2M+48.6%	$10.9M	N/A	N/A	N/A
Accounts Receivable	$865.1M+27.9%	$676.3M+88.9%	$358.0M+106.8%	$173.2M-64.2%	$483.1M+699.8%	$60.4M-14.8%	$70.9M+72.6%	$41.1M+39.5%	$29.4M	N/A	N/A	N/A
Long-Term Investments	$61.7M-52.2%	$128.9M+43.8%	$89.6M-2.3%	$91.8M-8.9%	$100.8M+104.3%	$49.3M	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	$109K0.0%	$109K0.0%	$109K0.0%	$109K0.0%	$109K0.0%	$109K	N/A	N/A	N/A
Total Liabilities	$3.8B+47.9%	$2.6B+14.1%	$2.3B+13.6%	$2.0B-16.9%	$2.4B+38.8%	$1.7B+173.1%	$633.9M+27.8%	$496.0M+36.9%	$362.2M+584.7%	$52.9M-75.8%	$218.5M	N/A
Current Liabilities	$1.8B-17.4%	$2.2B+22.4%	$1.8B+23.3%	$1.5B-8.2%	$1.6B+48.8%	$1.1B+246.5%	$310.3M+25.9%	$246.5M+64.3%	$150.0M+327.8%	$35.1M-0.3%	$35.2M	N/A
Non-Current Liabilities	$2.0B+434.7%	$373.8M-18.4%	$457.8M-13.2%	$527.4M-34.4%	$803.4M+22.4%	$656.3M+102.8%	$323.6M+29.7%	$249.6M+17.6%	$212.3M+1089.3%	$17.8M+145.4%	$7.3M	N/A
Long-Term Debt	$961.9M+477.8%	$166.5M-15.8%	$197.6M-5.5%	$209.1M+3.5%	$202.1M+10.1%	$183.6M+120.4%	$83.3M+104.3%	$40.8M+342.3%	$9.2M-46.6%	$17.3M	N/A	N/A
Total Equity	$4.4B+30.9%	$3.3B-5.8%	$3.5B-19.3%	$4.4B-28.5%	$6.1B+58.5%	$3.9B+302.1%	$962.2M-44.7%	$1.7B+159.7%	$669.8M+89.8%	$352.9M+446.8%	-$101.8M-91.9%	-$53.0M
Retained Earnings	-$8.3B+3.3%	-$8.6B-8.1%	-$8.0B-12.5%	-$7.1B-39.5%	-$5.1B-42.9%	-$3.6B-81.6%	-$2.0B-94.2%	-$1.0B-204.7%	-$330.5M-39.2%	-$237.4M-100.9%	-$118.2M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$9.2B+45.7%	$8.6B+46.4%	$8.2B+38.3%	$7.6B+30.9%	$6.3B+10.3%	$5.8B+3.1%	$5.9B+2.0%	$5.8B+5.5%
Current Assets	$7.2B+67.4%	$6.6B+69.4%	$6.2B+56.2%	$5.7B+44.8%	$4.3B+12.3%	$3.9B-0.3%	$4.0B-5.0%	$3.9B-3.5%
Cash & Equivalents	$5.1B+85.0%	$4.8B+90.4%	$4.5B+73.1%	$4.0B+49.4%	$2.8B+6.3%	$2.5B-9.9%	$2.6B-17.2%	$2.7B-11.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%
Inventory	$732.6M+45.7%	$681.6M+37.8%	$608.2M+22.9%	$531.7M+23.2%	$502.9M+13.4%	$494.7M+10.6%	$495.0M+19.0%	$431.7M+36.2%
Accounts Receivable	$1.1B+37.0%	$938.0M+30.8%	$865.1M+27.9%	$863.3M+51.7%	$770.8M+45.6%	$717.2M+64.8%	$676.3M+88.9%	$569.0M+84.1%
Long-Term Investments	$66.1M-44.7%	$66.0M-45.5%	$61.7M-52.2%	$100.7M-27.2%	$119.5M-14.5%	$121.1M-15.6%	$128.9M+43.8%	$138.2M+54.8%
Total Liabilities	$4.0B+58.3%	$3.8B+62.0%	$3.8B+47.9%	$3.5B+46.3%	$2.5B+7.8%	$2.3B+1.5%	$2.6B+14.1%	$2.4B+35.9%
Current Liabilities	$2.1B-4.1%	$1.8B-8.7%	$1.8B-17.4%	$2.4B+16.9%	$2.2B+14.0%	$2.0B+5.4%	$2.2B+22.4%	$2.0B+57.8%
Non-Current Liabilities	$1.9B+491.8%	$2.0B+453.1%	$2.0B+434.7%	$1.1B+207.2%	$318.1M-21.9%	$358.3M-15.8%	$373.8M-18.4%	$369.5M-22.8%
Long-Term Debt	$882.2M+503.8%	$962.5M+501.0%	$961.9M+477.8%	N/A	$146.1M-21.1%	$160.2M-19.5%	$166.5M-15.8%	$187.5M-7.4%
Total Equity	$5.2B+37.2%	$4.8B+36.0%	$4.4B+30.9%	$4.1B+20.2%	$3.8B+12.0%	$3.5B+4.1%	$3.3B-5.8%	$3.4B-8.7%
Retained Earnings	-$7.9B+7.7%	-$8.1B+6.0%	-$8.3B+3.3%	-$8.4B+0.8%	-$8.5B-2.1%	-$8.6B-4.8%	-$8.6B-8.1%	-$8.5B-11.3%

Not reported in any period shown, so not listed: Goodwill.

BEIGF Cash Flow Statement

BEIGF quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	$1.5B	$1.1B+901.8%	-$140.6M+87.8%	-$1.2B+22.7%	-$1.5B-15.2%	-$1.3B-1.2%	-$1.3B-71.1%	-$750.3M-37.0%	-$547.7M-4395.1%	$12.8M+114.2%	-$89.5M-124.7%	-$39.8M-358.3%	-$8.7M
Depreciation & Amortization	N/A	$141.7M-17.5%	$171.8M+95.9%	$87.7M+32.3%	$66.3M+42.7%	$46.5M+46.1%	$31.8M+70.8%	$18.6M+79.2%	$10.4M+118.3%	$4.8M+149.2%	$1.9M+23.6%	$1.5M-0.8%	$1.6M
Stock-Based Compensation	N/A	$510.9M+15.7%	$441.6M+20.1%	$367.6M+21.3%	$303.2M+25.9%	$240.7M+31.2%	$183.5M+36.8%	$134.2M+54.0%	$87.1M+103.3%	$42.9M+303.4%	$10.6M+4.1%	$10.2M+53.8%	$6.6M
Capital Expenditures	$153.9M	$185.8M-62.3%	$492.7M-12.3%	$561.9M+72.7%	$325.4M+23.8%	$262.9M+123.8%	$117.5M+31.1%	$89.6M+27.5%	$70.3M+51.6%	$46.4M+97.3%	$23.5M+342.3%	$5.3M+712.5%	$654K
Free Cash Flow	$1.3B	$941.7M+248.7%	-$633.3M+63.2%	-$1.7B+5.6%	-$1.8B-16.7%	-$1.6B-11.5%	-$1.4B-66.8%	-$839.9M-35.9%	-$618.0M-1738.1%	-$33.6M+70.2%	-$113.0M-150.3%	-$45.2M-383.1%	-$9.3M
Investing Cash Flow	-$182.5M	-$276.2M+49.6%	-$548.4M-1013.9%	$60.0M-94.4%	$1.1B+68.1%	$640.7M+120.2%	-$3.2B-671.7%	$554.2M+186.9%	-$637.6M-78.9%	-$356.3M-60.6%	-$221.8M-276.6%	-$58.9M	N/A
Financing Cash Flow	$1.1B	$1.1B+447.7%	$193.4M-53.6%	$416.5M+2295.3%	-$19.0M-100.5%	$3.6B-30.1%	$5.2B+5972.4%	$85.7M-94.9%	$1.7B+244.8%	$490.4M+28.7%	$380.9M+269.1%	$103.2M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$462.8M+75.6%	$201.3M+356.7%	$417.3M+455.3%	$402.6M+113.7%	$263.6M+375.8%	$44.1M+114.3%	$75.2M+133.9%	$188.4M+341.0%
Depreciation & Amortization	$40.5M+13.8%	$41.1M+25.4%	$36.0M-28.4%	$37.3M-47.7%	$35.6M+42.9%	$32.8M+29.7%	$50.2M+110.9%	$71.3M+231.4%
Stock-Based Compensation	$137.5M-8.7%	$123.4M+29.2%	N/A	$140.8M+22.8%	$150.6M+15.2%	$95.5M+7.7%	N/A	$114.6M+19.2%
Capital Expenditures	$27.5M-37.3%	$40.8M-27.7%	$37.5M-59.4%	$48.1M-64.0%	$43.8M-60.1%	$56.4M-64.0%	$92.5M-41.1%	$133.7M-15.3%
Free Cash Flow	$435.3M+98.1%	$160.5M+1402.6%	$379.8M+2293.0%	$354.5M+547.9%	$219.8M+206.9%	-$12.3M+97.4%	-$17.3M+95.4%	$54.7M+123.2%
Investing Cash Flow	-$49.4M+25.9%	-$45.5M+62.7%	-$38.3M+59.0%	-$49.3M+63.2%	-$66.6M+40.0%	-$121.9M+41.9%	-$93.6M-49.6%	-$133.9M+28.1%
Financing Cash Flow	-$6.1M-117.3%	$68.6M+303.2%	$96.9M+2243.1%	$961.3M+7491.8%	$35.0M+52.2%	-$33.8M-120.8%	-$4.5M-101.3%	$12.7M+116.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BEIGF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BEIGF quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Gross Margin	87.5%+3.1pp	84.4%-0.1pp	84.5%+4.8pp	79.8%-6.2pp	86.0%+8.9pp	77.1%-6.3pp	83.4%-2.1pp	85.5%-12.4pp	97.9%-2.1pp	100.0%	N/A	N/A
Operating Margin	8.4%+23.3pp	-14.9%+34.2pp	-49.1%	-126.4%	-122.3%	-536.7%	-224.2%	-356.1%	-41.3%	-10940.2%	-643.7%	-120.9%
Net Margin	5.4%+22.3pp	-16.9%+18.9pp	-35.9%	-141.5%	-123.9%	-526.1%	-221.5%	-339.9%	-39.1%	-11141.8%	-647.7%	-140.2%
Return on Equity	6.6%+25.9pp	-19.4%+5.6pp	-24.9%+20.8pp	-45.7%-21.9pp	-23.8%+18.2pp	-42.0%+56.6pp	-98.6%-59.9pp	-38.7%-24.8pp	-13.9%+19.9pp	-33.8%	N/A	N/A
Return on Assets	3.5%+14.4pp	-10.9%+4.3pp	-15.2%+16.2pp	-31.4%-14.3pp	-17.1%+11.9pp	-29.0%+29.8pp	-58.8%-28.9pp	-29.9%-21.1pp	-8.9%+20.5pp	-29.4%+19.5pp	-48.9%	N/A
Current Ratio	3.41+1.6x	1.80-0.5x	2.32-1.2x	3.55-1.2x	4.76+0.1x	4.61+0.8x	3.78-4.1x	7.89+1.8x	6.09-4.6x	10.68+7.7x	3.02	N/A
Debt-to-Equity	0.22+0.2x	0.050.0x	0.060.0x	0.050.0x	0.030.0x	0.050.0x	0.09+0.1x	0.020.0x	0.010.0x	0.05	N/A	N/A
Asset Turnover	0.650.0x	0.64+0.2x	0.42+0.2x	0.22+0.1x	0.14+0.1x	0.06-0.2x	0.27+0.2x	0.09-0.1x	0.23+0.2x	0.00-0.1x	0.08	N/A
FCF Margin	17.6%+34.3pp	-16.6%+53.3pp	-69.9%	-128.7%	-132.8%	-453.6%	-196.1%	-311.8%	-14.1%	-10562.1%	-512.2%	-71.7%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	89.8%+2.3pp	88.9%+3.7pp	90.5%+4.7pp	86.1%+3.1pp	87.5%+2.4pp	85.2%+1.8pp	85.8%+2.4pp	83.0%-4.7pp
Operating Margin	19.1%+12.4pp	16.5%+15.5pp	12.3%+19.4pp	11.6%+23.6pp	6.7%+18.2pp	1.0%+35.8pp	-7.0%+53.5pp	-12.0%+5.1pp
Net Margin	13.9%+6.7pp	15.0%+14.9pp	4.4%+17.9pp	8.8%+21.0pp	7.2%+20.1pp	0.1%+33.5pp	-13.5%+44.5pp	-12.1%-39.7pp
Return on Equity	4.6%+2.1pp	4.8%+4.7pp	1.5%+6.1pp	3.0%+6.6pp	2.5%+6.1pp	0.0%+7.5pp	-4.6%+5.8pp	-3.5%-9.3pp
Return on Assets	2.6%+1.1pp	2.7%+2.6pp	0.8%+3.4pp	1.6%+3.7pp	1.5%+3.6pp	0.0%+4.5pp	-2.6%+3.8pp	-2.1%-6.0pp
Current Ratio	3.40+1.5x	3.64+1.7x	3.41+1.6x	2.39+0.5x	1.950.0x	1.96-0.1x	1.80-0.5x	1.93-1.2x
Debt-to-Equity	0.17+0.1x	0.20+0.2x	0.22+0.2x	0.85+0.8x	0.040.0x	0.050.0x	0.050.0x	0.050.0x
Asset Turnover	0.190.0x	0.180.0x	0.180.0x	0.180.0x	0.210.0x	0.19+0.1x	0.19+0.1x	0.170.0x
FCF Margin	25.5%+8.8pp	10.6%+11.7pp	25.4%+26.9pp	25.1%+19.6pp	16.7%+38.8pp	-1.1%+60.8pp	-1.5%+58.1pp	5.5%+35.7pp

Where BEONE MEDICINES LTD Ranks

Frequently Asked Questions

What is BEONE MEDICINES LTD's annual revenue?

BEONE MEDICINES LTD (BEIGF) reported $5.3B in total revenue for fiscal year 2025. This represents a 40.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BEONE MEDICINES LTD's revenue growing?

BEONE MEDICINES LTD (BEIGF) revenue grew by 40.2% year-over-year, from $3.8B to $5.3B in fiscal year 2025.

Is BEONE MEDICINES LTD profitable?

Yes, BEONE MEDICINES LTD (BEIGF) reported a net income of $286.9M in fiscal year 2025, with a net profit margin of 5.4%.

What is BEONE MEDICINES LTD's EBITDA?

BEONE MEDICINES LTD (BEIGF) had EBITDA of $588.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does BEONE MEDICINES LTD have?

As of fiscal year 2025, BEONE MEDICINES LTD (BEIGF) had $4.5B in cash and equivalents against $961.9M in long-term debt.

What is BEONE MEDICINES LTD's gross margin?

BEONE MEDICINES LTD (BEIGF) had a gross margin of 87.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BEONE MEDICINES LTD's operating margin?

BEONE MEDICINES LTD (BEIGF) had an operating margin of 8.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is BEONE MEDICINES LTD's net profit margin?

BEONE MEDICINES LTD (BEIGF) had a net profit margin of 5.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is BEONE MEDICINES LTD's return on equity (ROE)?

BEONE MEDICINES LTD (BEIGF) has a return on equity of 6.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BEONE MEDICINES LTD's free cash flow?

BEONE MEDICINES LTD (BEIGF) generated $941.7M in free cash flow during fiscal year 2025. This represents a 248.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is BEONE MEDICINES LTD's operating cash flow?

BEONE MEDICINES LTD (BEIGF) generated $1.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BEONE MEDICINES LTD's total assets?

BEONE MEDICINES LTD (BEIGF) had $8.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are BEONE MEDICINES LTD's capital expenditures?

BEONE MEDICINES LTD (BEIGF) invested $185.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does BEONE MEDICINES LTD spend on research and development?

BEONE MEDICINES LTD (BEIGF) invested $2.1B in research and development during fiscal year 2025.

How many shares does BEONE MEDICINES LTD have outstanding?

BEONE MEDICINES LTD (BEIGF) had 1.44B shares outstanding as of fiscal year 2025.

What is BEONE MEDICINES LTD's current ratio?

BEONE MEDICINES LTD (BEIGF) had a current ratio of 3.41 as of fiscal year 2025, which is generally considered healthy.

What is BEONE MEDICINES LTD's debt-to-equity ratio?

BEONE MEDICINES LTD (BEIGF) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BEONE MEDICINES LTD's return on assets (ROA)?

BEONE MEDICINES LTD (BEIGF) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BEONE MEDICINES LTD's Altman Z-Score?

BEONE MEDICINES LTD (BEIGF) has an Altman Z-Score of 5.12, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is BEONE MEDICINES LTD's Piotroski F-Score?

BEONE MEDICINES LTD (BEIGF) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BEONE MEDICINES LTD's earnings high quality?

BEONE MEDICINES LTD (BEIGF) has an earnings quality ratio of 3.93x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BEONE MEDICINES LTD cover its interest payments?

BEONE MEDICINES LTD (BEIGF) has an interest coverage ratio of 8.95x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.